Pediatrix Medical Group/$MD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pediatrix Medical Group

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Ticker

$MD
Sector

Primary listing

NYSE

Employees

4,120

MD Metrics

BasicAdvanced
$1.4B
12.86
$1.29
1.21
-

What the Analysts think about MD

Analyst ratings (Buy, Hold, Sell) for Pediatrix Medical Group stock.

Bulls say / Bears say

Pediatrix posted Q2 adjusted EPS of $0.53, beating consensus by 25% and driving a 6.0% increase in NICU days, leading management to raise its full-year adjusted EBITDA outlook to $245–$255 million (Investing.com).
In Q1 2025, Pediatrix reported net revenue of $458 million and grew adjusted EPS to $0.33 from $0.20 year-over-year, with $49 million in adjusted EBITDA, prompting management to increase its full-year 2025 EBITDA outlook (Business Wire).
By March 31, 2025, Pediatrix reduced net debt to $612.6 million from $617.7 million at year-end 2024 and improved Q1 cash flow use to $116.1 million from $122.6 million a year earlier, demonstrating increased balance sheet efficiency (Nasdaq).
Pediatrix’s Q2 revenue was $468.8 million, down 7.0% year-over-year, mainly due to practice dispositions which offset growth in same-unit revenue (Investing.com).
Cash and cash equivalents dropped to $99.0 million by Q1 2025 from $229.9 million at the end of 2024, reflecting significant seasonal cash outflows for incentive compensation and benefit payments (Nasdaq).
With just $1.3 million left under its $500 million share repurchase program as of March 31, 2025, Pediatrix has little capacity for further capital returns, which could weaken support for shareholder value (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

MD Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MD Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Pediatrix Medical Group stock | $MD Share Price | Lightyear